How have national institutions and committees from EU member states positioned themselves regarding the use of gene editing in agriculture? To answer this question, this article examines and compares 11 official reports and position statements from 7 European countries: Germany, France, the Netherlands, Italy, Spain, Denmark, and Sweden. The various kinds of issues that are addressed and arguments that are made in the reports are coded into large categories (innovation, risk, ethics, legislation, etc.) and are analyzed. The paper discusses the main similarities and differences in terms of how the governance of gene editing is problematized. In doing so, the paper aims to provide a useful resource to broaden debates on the future regulation of gene editing within and beyond Europe. 1 We have searched for reports and statements from all 28 EU member states, with the exception of the UK as its future membership of the EU is uncertain. According to our search, in only 7 countries reports on gene editing have been published. This does not mean, however, that other EU member states have not reflected upon the issue: Eriksson (2018) has provided a detailed list with statements and opinions by EU actors that, beyond the countries we identified, also includes Finland.
Introduction
Recent responses from policy makers concerning the regulation of gene editing in the field of agriculture have shown remarkable divergences. Consider, on the one hand, the position of the US Department of Agriculture (2018): crops modified via gene editing "do not require regulatory oversight." The US Department of Agriculture considers gene edited crops as innovative, safe, and healthy. Consider, on the other hand, the ruling of the EU Court of Justice (2018): gene edited organisms "are GMOs and are, in principle, subject to the obligations laid down by the GMO directive [EU Directive 2001/18/EC]". While establishing an equivalence between gene edited organisms and GMOs, the EU Court of Justice argues that gene edited organisms can potentially be risky, and stresses the need to respect the precautionary principle.
While the position at the EU level is clear-cut, what about positionings within individual European member states? How have national institutions and committees positioned themselves regarding the use of gene editing in agriculture?
Do they have similar views on the issue or are there significant differences?
To answer these questions this article examines official reports and position statements from seven European countries: Germany, France, the Netherlands, Italy, Spain, Denmark, and Sweden. We have decided to focus on these seven countries for they are the only European countries in which at least one official statement regarding the use and regulation of gene editing in agriculture has been published. 1
Context
Today the most prominent gene editing technique is CRISPR/Cas9. CRISPR (for Clustered regularly interspaced short palindromic repeats) sequences have first been described in 1987 and in the 2000s their capacity to "edit" genes has been recognized. The CRISPR/Cas9 technology-often called "gene scissors"-makes it possible to change genetic sequences easier, quicker and cheaper than traditional biotechnology methods and has thus been celebrated as the iPhone of biotechnology and the greatest advance in biotechnology since the PCR machine.
2015 is the year that CRISPR/Cas9 made it to the headlines of many academic journals as well as media outlets. The publication in April 2015 of an article on the modification of human embryos in the journal Protein & Cell (Liang et al. 2015) raised international concern and calls for a moratorium were published in journals such as Nature (Lanphier et al. 2015) and Science (Baltimore et al. 2015) . From 2015, CRISPR/Cas9 became the object of wide and rich debates. Concerns have been raised about ethical issues, about economic issues related to patenting, about environmental and health risks, and about the possibility to produce new kinds of weapons. The issues raised resemble the types of issues that can be observed in debates around GMOs and synthetic biology, which generally revolve around ELSI issues, that is the ethical, legal, and social implications of science (Baumann 2016) .
At the end of 2015, the first international summit on human gene editing was held in Washington (Jasanoff et al. 2015) . After this summit, numerous countries have issued reports or statements about human gene editing, including the UK, the US, Germany, France, the Netherlands, India, Denmark, Canada, and Australia. Various other conferences such as CRISPRcon have been organised (since 2017) to address scientific, ethical, legal and policy issues. Gene editing then broke again the headlines in November 2018 when scientist He Jiankui announced that he had modified the embryos of twins via gene editing; an announcement made just a few days before the second international summit on human genome editing in Hong Kong (Meyer 2018) . As in 2015, the organizing committee released a statement about the use of gene editing in human embryos and many countries and scientific institutions issued position statements thereafter.
While human gene editing has been much discussed and written about, much less has been written on the use of gene editing in agriculture and its implications in terms of governance, regulation, economics, social and ethical issues. There have been, on the one hand, several reports on the topic-for example the report New Techniques in Agricultural Biotechnology published by the European Commission in 2017as well as international conferences on the topic, such as Genome Editing: Applications in Agriculture-Implications for Health, Environment and Regulation held at the OECD in 2018. On the other hand, only a few academic articles have discussed and examined the wider implications of gene editing. Gutzmann et al. (2017) discuss the need for interdisciplinarity and public engagement when reflecting upon the ethics and governance of CRISPR-based gene drives in agriculture. They conclude: "Scientists, social scientists, regulators, advocacy groups, and public audiences have been and must continue to engage clearly and candidly with one another to shape the future of this technology". Holman (2019) has compared regulatory frameworks, in particular between the US, who are moving towards less regulation, and the EU, who intents to regulate gene editing via the "same burdensome regime" than for GMOs. A wide scope is provided by Eriksson et al. (2019) , who look into regulations in Argentina, Brazil, Chile, Colombia, Canada, the United States and Australia in comparison to the EU approach. They also discuss some of the concerns raised in the aftermath of the ruling of the EU Court of Justice: concerns with trade disruptions, agricultural innovation, and the difficulty to detect and label gene edited products. The present article aims to contribute to this recent and emerging academic literature on the social, ethical, legal and political aspects of the use of gene editing in agriculture. Its originality consists in examining and comparing how different councils, commissions and/or institutions within the EU have addressed gene editing. Such an approach is useful, we hope, because governance and public debates on gene editing occur both on national and transnational levels and since comparisons can reveal the specificities of a given position, and point to commonalities and potential divergences between countries and institutions.
Methods and results
We have selected and analysed altogether 11 texts published in 7 countries (see Table 1 ). The reports have all been published from 2015 onwards, which doesn't come as a surprise since gene editing rose to prominence in 2015 both within and beyond academic circles. There is a notable heterogeneity regarding the institutions that have published them: independent councils (i.e. the French Haut Conseil des Biotechnologies, the Danish Council on Ethics); ministerial commissions (i.e. the Spanish Comisión nacional de bioseguridad) and intra-ministerial commissions (i.e. the Italian Comitato Nazionale per la Biosicurezza, le Biotecnologie e le Scienze della Vita); as well as scientific institutions (i.e. the common ethics committee of INRA, CIRAD, and IFRE-MER, the Max Planck Society). While the provenances and forms of these texts are heterogenous, they were all written in response to regulatory concerns associated with the future governance of-and debates on-gene editing and all include recommendations.
To examine the content of these texts in more detail, we have used what social scientists call a "grounded method": we have scrutinized the texts to seek for the various kinds of issues that are addressed and arguments that are mobilised, and we then coded these into eight large groups (innovation, risk, ethics, etc.) . To these eight categories we added a ninth rubric: the reports' recommendations (see Table 2 ). In a second round of analysis, we have examined if and how, in each of these 11 reports, the eight themes have been addressed and what kinds of recommendations they draw. Table 2 provides a summary of the results of our analysis.
Discussion
Some texts take a strong stance in favor of the exclusion of gene editing from current regulation making claims about the negative consequences for science and economy should the EU regulation (i.e. EU Directive 2001/18/EC) not be renewed. This is the case, for instance, in the two reports from Italy. The 2016 SIGA/SIBV report says that it would be a "serious mistake" to qualify as GMOs gene edited organisms with mutations that are indistinguishable from spontaneous ones, and that the "remake of European GMO history" will lead to "a nonsense of logic, a scientific absurdity, a legal mess and an economic damage altogether". The 2017 CNBBSV report, albeit a bit softer in tone, is also clearly in favour of not regulating gene editing, arguing that there are only "minor risks", and that the 2001 EU directive is "inadequate" and that regulation should be "purely product-oriented" (and not process-oriented). In a section devoted to market issues, concerns are raised about "grave repercussions on strategic sectors […] with an inevitable loss of international market".
The position of the Swedish Board of Agriculture-an assessment of the (mostly negative) consequences of the EU Court of Justice ruling-is also in favour of deregulating gene editing. It stresses that for "many researchers, the ruling is perceived as very problematic." According to the report, many things will be "lost" due to the ruling: "Made investments in patent, staff, research, product development and knowledge", "competence", "competitiveness", "control of plant breeding". Both the positive assessment of gene editing, as well as the negative assessment of the ruling are exemplified by the following quote:
"The ruling will have negative effects on the national economy when it comes to both plant and animal production. It is counter-productive to make it more difficult to use a technique with high precision and with several benefits compared to "older" techniques. Genome editing is a brilliant example of technical development being the most important factor to be able to deal with challenges regarding food supply, resource management, climate adaptation and the environment."
In the same vein, the report of the Danish Council on Ethics holds a position which is largely in favour of a renewal of EU regulations while putting a stronger emphasis on the solution of current planetary crises. A general bottom-line of the Danish Council on Ethics is that CRISPR does not carry more or less risk than traditional gene modification, and that, given this "fact", humanity can no longer "afford" not to use CRISPR. To strengthen this utilitarian position, the authors repeatedly refer to the potential role that genome editing could play "in achieving several of the UN's Sustainable Development Goals from 2015". Beyond that, the authors accuse the existing EU regulatory framework of being "paradoxical" while underlining that this paradoxicality "raises the question of whether it is ethically problematic if the legislation obstructs the development and marketing of GMOs, e.g. those with positive effects, if they are not deemed more risky than similar conventional varieties."
Despite this vigorous argumentation in favor of CRISPR, the report closes with somewhat fragmented recommendations on how to govern gene editing in the future. In these recommendations "some members" (the large majority) of the Danish Council on Ethics provide practical suggestions on how to adapt current EU regulation, while "one member" is granted the space to express that he "cannot support measures to ease the authorisation system for GMOs."
At the other end of the spectrum is the 2018 report by the Comité consultatif commun d'éthique INRA-CIRAD-IFRE-MER. This report is the most critical, reflexive and analytical in our corpus of texts. The report argues, for instance, that "it is important not to be blinded by short-term benefits but to take the time to evaluate long-term risks" and that an "upstream inclusive and collective reflexion" is needed. It situates gene editing within larger debates about the models and politics of agriculture; it discusses controversies and contestations; and it reflects about issues that are not present in any other report, such as recent developments in the field of agroecology as well as matters of public participation, social justice, and open source. The ten recommendations of the report can be roughly summarized as a call for reflexivity, openness and vigilance (for example: consider the forms of agriculture, economy and society in relation to CRISPR/ Cas9; foster interdisciplinary research; discuss about regulation and intellectual property issues). The report by the Danish Council on Ethics is somewhat similar to the INRA-CIRAD-IFREMER report in terms of its scope: both reports are interdisciplinary (and their authors include philosophers, ethicists, plant scientists, environmental scientists, etc.) and they provide a much more systemic analysis than the other reports.
To put it bluntly, we can identify three kinds of reports in our corpus: interdisciplinary/systematic ones (France, Denmark); reports that talk in the name of science and offer rather cautions assessments regarding technological advantages (Netherlands, Germany, Spain); and those with a strong normative and affirmative view (Italy, Sweden). 
Similarities and differences within themes
The reports provide a more or less broad view of the use of gene editing in agriculture. They focus not only on the technical aspects of gene editing, but also on risks and legislation. Some issues are, however, present in only a few reports, such as ethics, intellectual property, and what we termed "epistemology" (arguments about the kind, importance and usefulness of knowledge produced). Let us look in more detail at how innovation, legislation, recommendations and the economy have been addressed in the texts 2 :
• The qualifications of gene editing (the theme "innovation") show remarkable similarity, with terms like "simple", "rapid", "efficient", "precise" being used in most reports. 3 • The legal implications of gene editing are also treated in a similar fashion: most reports argue for the need of a "revision" and/or "updating" of current legislation, because there are "uncertainties". Most reports also recommend that legislation should be based on products, and not the processes of genetic modification anymore. • There are notable differences regarding the specific recommendations that are given. On the one hand, there are reports that have a moderate view: they recommend to "amend" and "clarify" legislation because it is "unclear" (i.e. the Netherlands, Germany, France). While these reports argue that legislation needs modification and further reflection, they refrain from saying what kinds of modifications should be done. On the other hand, there are reports that take a more normative stance and argue, for example, that gene edited organisms "should be excluded" from legislation (Italy). • Economic issues are also treated differently in the reports.
First, in the German statements economic aspects are virtually absent. 4 Second, in the reports from Spain and the Netherlands, they are mentioned very briefly, usually in a couple of sentences. Quite frequently these brief considerations of the economic issues underline the importance of using gene editing to maintain or improve a particular branch of agricultural production that is historically intertwined with the national territory. For example, the position of the Royal Netherlands Academy of Arts and Sciences is that a renewal of the regulation in the EU is needed in the name of horticulture. Third, there are reports, like the Italian, Swedish and French ones, that treat economic issues in great depth on several pages. The French INRA-CIRAD-IFREMER report discusses for instance economic risks and the tensions between the industrial paradigm (concerned with performance and control) and the agro-ecological paradigm (concerned with protection and cooperation), and the HCB report reflects upon commercialisation, competitiveness, traceability, and consumer choices. In the report by the Swedish Board of Agriculture, the negative consequences of the EU Court of Justice ruling on the economy are evaluated and potatoes, rapeseed and barley are discussed as examples of crops that are important for Swedish agriculture. The 2017 CNBBSV report contains discussions of specific sectors in agriculture (rice, grapes, wheat, etc.) and the strategic interest thereof for Italy. It is interesting to note here that the examples given are always plants but very rarely animals.
Argumentative patterns in relation to GMOs
In addition to the themes that we identified and analysed, we observed that GMOs often serve as a reference frame to make arguments about gene editing. On the one hand, this doesn't come as a surprise since Directive 2001/18/EC is the key legal reference point and since the key question can be summarised as "Should gene edited organisms (GEOs) be considered as GMOs or not?". On the other hand, however, references to GMOs are not limited to legal aspects only. In fact, several argumentative patterns in relation to GMOs can be noted:
1. GEOs are better and different than GMOs: they are safer, more precise, and quicker and cheaper to produce. The argument here is that with regards to the history of GMOs there has been a differentiation and revolution. 2. GEOs are comparable to GMOs: there is no scientific evidence that GMOs pose a risk, they can thus be considered as safe. Therefore GEOs are also safe. This argument relies on the comparability between GMOs and GEOs and-unlike the argument above-upon the historical and technical continuity between them. 3a. GEOs are not GMOs in terms of legislation. GEOs should not be regulated as GMOs. The problem with pace and asynchronicity is put forward here: legislation is seen as "outdated" with regards to new knowledge and new techniques. 3b. GEOs are not GMOs in terms of nature. Since it will not be possible to distinguish most GEOs from natural mutations, GEOs should be excluded from any legal framework. In other words, GEOs' indistinguishability from nature should lead to their unaccountability in law.
An illustrative example for this modular use of references to GMOs is provided by the report of the Danish Council on Ethics. On the one hand, the authors frequently draw comparisons between "20 years of GMO risk assessments" and the "[a]bsence of particular risks" of GEOs. On the other hand, they repeatedly refer to the technical difference of "CRISPR-induced mutations" and "traditional mutagenesis", to argue that GMOs and GEOs should not be legislated in the same way. In other words, from the Danish Council on Ethics' point of view it seems possible to separate GEOs as objects of risk/non-risk from GEOs as objects of legislation.
Concluding remarks
Gene edited organisms have become, over the past four years, the topic of a wide array of texts: reports, statements, rulings, etc. While some of these texts have been published by scientific institutions, others have been published by ministerial commissions and advisory councils that are involved in concrete acts of doing politics. It is thus fruitful to ask a wider question here: What kind of objects are gene edited organisms and how can we grasp their political dimensions? To answer this question, let us consider the following quote by Vytenis Andriukaitis, the current EU commissioner for Health and Food Safety:
"new breeding techniques can help us tackle some profound challenges such as food security, food intolerances, or climate change. Examples include lowgluten, non-transgenic wheat […] Or potatoes with a non-browning trait and producing less asparagine have been developed through gene editing. These potatoes provide the potential for the formation of acrylamide to be reduced by 60-70% when potatoes are baked, fried or roasted at high temperatures. (This could completely 'save' Belgium fries)" (Andriukaitis, CRIS-PRCon 2019).
Gene edited organisms are very specific objects. They bring together not only technological and scientific considerations but also issues to do with consumers and health. They are socio-technical objects. The pun regarding the "saving" of Belgian fries reveals another important facet of gene edited organisms: they are also geopolitical objects. In the reports we have analysed, Dutch horticulture, Italian grapes, and Swedish potatoes have been put forward as relevant issues. Even the call for the "advancement of European science" made in the 2019 report by the Comisión nacional de bioseguridad is not only an argument about knowledge, but also about politics. In a similar way, the report by the Danish Council on Ethics interweaves its specific argument for a renewal of the EU legislation regarding GEOs with more general references to UN Sustainable Development Goals that might be attained by means of new gene editing tools. In other words, the report translates complex and planetary problems such as climate change and hunger into the less complex (and easier-to-imagine) problems of finding the right tools and indicators.
These kinds of entanglements between the technical, the social and the political are particularly interesting to examine and compare. While we have analysed these entanglements across national and institutional positions, there is scope for further analysing national policies in more detail. This could be done, for instance, by looking more specifically at the history and the making of policies in a given country/institution and how different kinds of expertise and scientific disciplines are mobilised in this process. If one moves beyond the neatly crafted world of policy reports and position statements, the picture gets more complex (and would require further analyses). 5 This could also entail an analysis of the objectification of gene editing: how are gene edited organisms rendered tangible, discussable and public via policy processes? How are they tied to national territories, identities, histories or products and how, if at all, does this "(re)nationalizing" of gene edited organisms matter within and beyond EU member states?
Given that gene edited organisms raise technical, social, ethical, legal and political issues, how are they to be governed? Our paper has shown that there are a number of similarities, but also a great number of differences in terms of how their governance is problematized. Some reports are the result of a framing that mainly focused on technology, risk and regulation, whereas other reports considered ethics, intellectual property, and societal issues as well. And while some reports considered gene editing in itself, others chose to situate gene editing within larger debates about agriculture, gene drives, medicine, public participation, and the responsibility of scientists. Given that the governance of gene editing can hardly be confined to national boundaries, expertise and policy about gene editing is also very likely to cross national borders. However, this is not necessarily an easy and smooth process: the divergences across positions within EU member states make a synthesis and common view difficult to achieve. Can diverse European policy options for GEOs co-exist and what consequences would this coexistence have? Asked differently: could gene editing become a "European object" (Laurent 2019) , and if so, how? The ruling of the EU Court of Justice is a key site which addresses this question. The ruling not only assesses the technical aspects of GEOs, it also defines and constitutes them as a very specific kind of object: an object that, in Europe, requires regulatory oversight. Whether one agrees with this ruling or not, further debates about the entanglement-and disentanglement-between the law and technology are to be expected. We hope that our paper will provide a useful resource to broaden debates on the future regulation of gene editing within and beyond Europe.
